AMEZINIUM METILSULFATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H12N3O.CH3O4S
Molecular Weight	313.33
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COS([O-])(=O)=O.COC1=CC(N)=CN=[N+]1C2=CC=CC=C2

InChI

InChIKey=ZEASXVYVFFXULL-UHFFFAOYSA-N

InChI=1S/C11H11N3O.CH4O4S/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10;1-5-6(2,3)4/h2-8,12H,1H3;1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	C11H11N3O
Molecular Weight	201.2245
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH4O4S
Molecular Weight	112.105
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://ds-pharma.jp/product/risumic/pdf/risumic_tab_interv.pdf
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/6873182

Amezinium is a sympathomimetic used for its vasopressor effects in the treatment of hypotensive states. Amezinium inhibited monoamine oxidase (MAO) activity. Amezinium antagonized the response to tyramine and blocked neuronal uptake of noradrenaline. Side effects revealed are: palpitation, headache, nausea/vomiting, hot flashes, high blood pressure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Amine oxidase [flavin-containing] A 14 Target ID: P58027 Gene ID: 403450.0 Gene Symbol: MAOA Target Organism: Canis lupus familiaris (Dog) (Canis familiaris) Sources: https://www.ncbi.nlm.nih.gov/pubmed/6873182	Inhibitor 8504	5.0 µM [IC50]
Amine oxidase [flavin-containing] B 11 Target ID: Q7YRB7 Gene ID: 403451.0 Gene Symbol: MAOB Target Organism: Canis lupus familiaris (Dog) (Canis familiaris) Sources: https://www.ncbi.nlm.nih.gov/pubmed/6873182	Inhibitor 8504	1.0 mM [IC50]
Alpha adrenergic receptor (Canis lupus) 2 Target ID: Alpha adrenergic receptor (Canis lupus) Sources: https://www.ncbi.nlm.nih.gov/pubmed/6873182	Blocker 555

Conditions

Condition	Modality	Targets	Highest Phase	Product
Essential hypotension 2 Sources: http://www.kegg.jp/medicus-bin/japic_med_product?id=00000102-001#00000102-001	Primary		Approved 8583	Risumic Approved Use Amezinium is indicated for the treatment of hypotensive states (essential hypotension, orthostatic hypotension). Launch Date 1991
Orthostatic hypotension 4 Sources: http://www.kegg.jp/medicus-bin/japic_med_product?id=00000102-001#00000102-001	Primary		Approved 8583	Risumic Approved Use Amezinium is indicated for the treatment of hypotensive states (essential hypotension, orthostatic hypotension). Launch Date 1991

C_max

Value	Dose	Analyte	Population
25.3 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
82 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
70.7 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
15.4 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
25.3 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
65.8 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
124.3 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
26.5 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/300119_2190022F1237_1_081_1F.pdf#page=17	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
741.6 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/300119_2190022F1237_1_081_1F.pdf#page=17	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
13.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
25.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
19.2 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25.5 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/300119_2190022F1237_1_081_1F.pdf#page=17	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
79.3% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=21			AMEZINIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12664248/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12664248/	Other AEs: voiding difficult... Other AEs: voiding difficult (20%) Sources: https://pubmed.ncbi.nlm.nih.gov/12664248/

AEs

AE	Significance	Dose	Population
voiding difficult	20%	15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12664248/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12664248/

PubMed

Title	Date	PubMed
Differences in skin sympathetic involvements between two chronic autonomic disorders: multiple system atrophy and pure autonomic failure.	2009-06	18805037
[Cathecholamine].	2004-06	15250291
Successful treatment of retrograde ejaculation with amezinium.	2003-05-15	12746100
Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy.	2003-02	12664248
Determination of amezinium in plasma by RP HPLC and its application to bioequivalence studies.	2002-03-06	11876436
[An autopsy case of pure autonomic failure with pathological features of Parkinson's disease].	2001-01	11433766
Pharmacological effect of amezinium on urethra and bladder of rabbits.	2001	11451005
Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa.	2000-12	11145175

Patents

Sample Use Guides

In Vivo Use Guide

Twice a day, 20 mg daily

Route of Administration: Oral

In Vitro Use Guide

Amezinium antagonized the response to tyramine and blocked neuronal uptake of noradrenaline m concentrations as low as 0.1 to 10 uM and therefore it was not surprising to find that in the presence of the lower concentration of Amezinium the effects of noradrenaline were potentiated (at the level of the ED50) by a factor of 3.5.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:31:46 GMT 2025` Edited by `admin` on `Mon Mar 31 18:31:46 GMT 2025`
Record UNII	03NR868ICX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMEZINIUM METILSULFATE

Official Name

English

AMEZINIUM METHYL SULFATE [MI]

Preferred Name

English

AMEZINIUM METILSULFATE [JAN]

Common Name

English

AMEZINIUM METILSULFATE [MART.]

Common Name

English

AMEZINIUM METILSULPHATE

Common Name

English

Amezinium metilsulfate [WHO-DD]

Common Name

English

4-AMINO-6-METHOXY-1-PHENYLPYRIDAZINIUM METHYL SULFATE

Systematic Name

English

amezinium metilsulfate [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC01CA25